Suprefort: clinical report on a tissue-derived preparation
Comparison in people · 2006
- What was studied
- 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- Main finding
- In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Glucose two hours after challenge, type 2 diabetes subgroup · 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. · Table 3 marks p < 0.05 versus usual care.
Reported findings and study design
The group table lists 22 treated and 17 controls with type 2 diabetes, and 12 treated and 8 controls with chronic pancreatitis. The diabetes section describes one 10 mg capsule twice daily before meals for 10 days (20 mg/day). The general methods describe one or two 10 mg capsules twice daily for 15 days (20–40 mg/day).
Population or model 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glucose two hours after challenge, type 2 diabetes subgroup | 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. | Table 3 marks p < 0.05 versus usual care. |
| Fasting glucose, type 2 diabetes subgroup | 5.8 ± 0.3 versus 6.6 ± 0.4 mmol/L. Baseline values were 7.9 ± 1.1 and 8.2 ± 0.9 mmol/L respectively. | The report marks significance against baseline for each arm. |
Group sizes are from Table 1. Allocation methods, changes to other medications and the short follow-up limit attribution.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source details
Institute report — commercial reproduction
Russian Medical Center report, methods and Tables 1–3, PDF pages 74–76.
Sources checked
Citation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Suprefort: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date